A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19 / 浙江大学学报·医学版
Journal of Zhejiang University. Medical sciences
; (6): 215-219, 2020.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-828550
Responsible library:
WPRO
ABSTRACT
OBJECTIVE@#To evaluate the efficacy and safety of hydroxychloroquine (HCQ) in the treatment of patients with moderate coronavirus disease 2019 (COVID-19).@*METHODS@#We prospectively enrolled 30 treatment-naïve patients with confirmed COVID-19 after informed consent at Shanghai Public Health Clinical Center. The patients were randomized 1:1 to HCQ group and the control group. Patients in HCQ group were given HCQ 400 mg per day for 5 days plus conventional treatments, while those in the control group were given conventional treatment only. The primary endpoint was negative conversion rate of SARS-CoV-2 nucleic acid in respiratory pharyngeal swab on days 7 after randomization. This study has been approved by the Ethics Committee of Shanghai Public Health Clinical Center and registered online (NCT04261517).@*RESULTS@#One patient in HCQ group developed to severe during the treatment. On day 7, nucleic acid of throat swabs was negative in 13 (86.7%) cases in the HCQ group and 14 (93.3%) cases in the control group (>0.05). The median duration from hospitalization to virus nucleic acid negative conservation was 4 (1,9) days in HCQ group, which is comparable to that in the control group [2 (1,4) days, Z=1.27, >0.05]. The median time for body temperature normalization in HCQ group was 1 (0,2) day after hospitalization, which was also comparable to that in the control group [1 (0,3) day]. Radiological progression was shown on CT images in 5 cases (33.3%) of the HCQ group and 7 cases (46.7%) of the control group, and all patients showed improvement in follow-up examinations. Four cases (26.7%) of the HCQ group and 3 cases (20%) of the control group had transient diarrhea and abnormal liver function (>0.05).@*CONCLUSIONS@#The prognosis of COVID-19 moderate patients is good. Larger sample size study are needed to investigate the effects of HCQ in the treatment of COVID-19. Subsequent research should determine better endpoint and fully consider the feasibility of experiments such as sample size.
Full text:
Available
Health context:
Neglected Diseases
/
SDG3 - Target 3.3 End transmission of communicable diseases
Health problem:
Diarrhea
/
Pneumonia
Database:
WPRIM (Western Pacific)
Main subject:
Pneumonia, Viral
/
RNA, Viral
/
Diagnostic Imaging
/
China
/
Pilot Projects
/
Treatment Outcome
/
Coronavirus Infections
/
Therapeutic Uses
/
Drug Therapy
/
Pandemics
Type of study:
Controlled clinical trial
/
Diagnostic study
Aspects:
Ethical aspects
Limits:
Humans
Country/Region as subject:
Asia
Language:
Chinese
Journal:
Journal of Zhejiang University. Medical sciences
Year:
2020
Document type:
Article